BLA for Cosibelimab Submitted to FDA for Management of Metastatic/Advanced Cutaneous SCC

Retrieved on: 2023-01-05 21:09:57

Tags for this article:

Click the tags to see associated articles and topics

BLA for Cosibelimab Submitted to FDA for Management of Metastatic/Advanced Cutaneous SCC. View article details on hiswai:

Excerpt

Cosibelimab is a fully human monoclonal antibody that directly binds to ... of severe hypersensitivity reaction to other monoclonal antibodies, ...

Article found on: www.cancernetwork.com